Home-based EEG treatments for chronic pain are a step closer after a specially-designed headset performed well in validation testing.
Affordable electroencephalography or EEG could widen access to this type of treatment and assessment, but rigorous validation of the tools is needed. Researchers from Neuroscience Research Australia (NeuRA) and UNSW Sydney evaluated a custom-developed central scalp EEG headset, PainWaive, with promising results.
“EEG is widely used in research and clinical practice to study brain function and to diagnose conditions such as epilepsy and sleep disorders,” said Dr Nahian Chowdhury.
“It is also used therapeutically in the form of neurofeedback, where individuals learn to modulate their brain activity in real time, providing a non-pharmacological option for conditions characterized by dysregulated oscillations, such as chronic pain.
“However, this has traditionally required on research-grade EEG systems, which require lengthy setup, precise electrode placement and trained staff. This creates substantial barriers to wider clinical use, particularly for people with impaired mobility, chronic illness, or those living in rural and remote regions.”
What is PainWaive?
Most available consumer-grade EEG systems target frontal or temporal regions for applications such as meditation, attention or sleep, with relatively little focus on central scalp activity, which has been shown to be altered in chronic pain populations.
PainWaive was developed by Professor Sylvia Gustin and Dr Negin Hesam-Shariati and evaluated to fill this gap, recording central scalp activity from C1 and C2 electrode positions.
“PainWaive was designed to be portable, wireless and home-based, offering a scalable alternative for neurofeedback applications,” said Professor Gustin.
“This study aimed to evaluate the test-retest reliability and cross-device consistency of PainWaive.
“Overall, the findings suggest that PainWaive can provide stable estimates of EEG features, but beta and theta are more sensitive to methodological decisions.”
The study involved 80 participants who completed two resting-state EEGs using PainWaive and a research-grade system called LiveAmp.
Overall, PainWaive demonstrated reliable measurement of central scalp EEG metrics, supporting repeated within-device monitoring.
What this means and what next
The study shows the potential of PainWaive as an EEG device for at-home use.
“Traditionally, measuring brain activity using EEG requires expensive equipment, specialist training a visit to a laboratory,” said Dr Hesam-Shariati.
“Our study shows that a much cheaper, easy-to-use headset can reliably measure important aspects of brain activity, opening up possibilities for monitoring and EEG-based treatments to be conducted in the comfort of people’s homes.”
PainWaive showed an expected level of reliability for an EEG device and the results provide valuable benchmarks for future studies using home-based EEG systems.
“The next step is to investigate whether PainWaive can be used to help people manage chronic pain through a technique called neurofeedback, where people receive real-time feedback about their brain activity and learn how to change it,” said co-first author, Joshua Rawsthorne.
“We want to test this in larger clinical studies and ultimately make the technology more accessible for people to use at home.”
“While chronic pain is our main focus, this technology could potentially be used in other areas, including mental health and sleep.”
The paper ‘Evaluation of PainWaive: A Consumer-grade EEG headset for remote EEG monitoring and neurofeedback research in chronic pain’ was published in npj Digital Medicine and is available here.